Sei Y Chung, Parker Kenee, Tanner Mitton, Ashleigh Halderman
{"title":"SMARCB1(ni -1)-缺陷鼻窦癌:一个进化的实体。","authors":"Sei Y Chung, Parker Kenee, Tanner Mitton, Ashleigh Halderman","doi":"10.1055/a-1996-1283","DOIUrl":null,"url":null,"abstract":"<p><p>SMARCB1(INI-1)-deficient sinonasal carcinoma is a rare, poorly differentiated neoplasm with a poor prognosis. Though historically most were identified as sinonasal undifferentiated carcinoma, we now understand it to be a distinct entity. There is currently a general consensus supporting multimodal therapy, though the optimal sequence of surgery, chemotherapy, and radiation has yet to be defined.</p>","PeriodicalId":44256,"journal":{"name":"Journal of Neurological Surgery Reports","volume":null,"pages":null},"PeriodicalIF":0.6000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4d/fc/10-1055-a-1996-1283.PMC9883109.pdf","citationCount":"0","resultStr":"{\"title\":\"SMARCB1(INI-1)-Deficient Sinonasal Carcinoma: An Evolving Entity.\",\"authors\":\"Sei Y Chung, Parker Kenee, Tanner Mitton, Ashleigh Halderman\",\"doi\":\"10.1055/a-1996-1283\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>SMARCB1(INI-1)-deficient sinonasal carcinoma is a rare, poorly differentiated neoplasm with a poor prognosis. Though historically most were identified as sinonasal undifferentiated carcinoma, we now understand it to be a distinct entity. There is currently a general consensus supporting multimodal therapy, though the optimal sequence of surgery, chemotherapy, and radiation has yet to be defined.</p>\",\"PeriodicalId\":44256,\"journal\":{\"name\":\"Journal of Neurological Surgery Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4d/fc/10-1055-a-1996-1283.PMC9883109.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Neurological Surgery Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/a-1996-1283\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neurological Surgery Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-1996-1283","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
SMARCB1(INI-1)-Deficient Sinonasal Carcinoma: An Evolving Entity.
SMARCB1(INI-1)-deficient sinonasal carcinoma is a rare, poorly differentiated neoplasm with a poor prognosis. Though historically most were identified as sinonasal undifferentiated carcinoma, we now understand it to be a distinct entity. There is currently a general consensus supporting multimodal therapy, though the optimal sequence of surgery, chemotherapy, and radiation has yet to be defined.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
